Resources
98 Results (showing 71 - 80)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/26/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment.
Posted 11/16/2022 (updated 3/27/2024)
In this cross-sectional study of 266 Medicaid MCO plans and 39 FFS programs, FFS programs offered more generous MOUD coverage, but a higher percentage of FFS programs imposed PA than MCO plans.
Posted 11/14/2022 (updated 3/27/2024)
In their new 2022 Clinical Practice Guideline, the Centers for Disease Control and Prevention (CDC) provides updated evidence and research on the risks and benefits of prescription opioids for acute, subacute, and chronic pain. These include dosing strategies, tapering and discontinuation, comparisons with nonopioid pain treatments, and risk mitigation strategies.
Posted 6/6/2022 (updated 3/27/2024)
There are many pathways of recovery from substance use disorder, and all are cause for celebration. This panel featured diverse faces and voices representing a variety of recovery experience including elements of medications for opioid use disorder, alcohol-free recreation, harm reduction mutual aid, outdoor hobbies, yoga and meditation, recovery-supportive housing, collegiate recovery, 12-step mutual aid, and more.
Posted 4/14/2023 (updated 3/27/2024)
Researchers evaluate The Kentucky Access to Recovery Program (KATR), which provides services to individuals recovering from opioid use in several counties in Eastern Kentucky, and conclude KATR demonstrates a potentially effective strategy for increasing health-related social services in rural areas.
Posted 6/3/2022 (updated 3/27/2024)
Creating and maintaining an open, safe, and inclusive setting that reflects warmth and promotes connection and belonging are essential elements of peer-led, peer-driven, social model recovery homes. Recovery housing and a social recovery approach offer a broad, holistic, multifaceted strategy for rural or urban communities. This presentation detailed the critical role of the Peer-Led, Peer-Driven Social Model of Recovery.
Patients Treated With Buprenorphine in Emergency Departments More Likely To Continue After Discharge
Posted 4/11/2023 (updated 3/27/2024)
In this cohort study of 17,428 Medicaid-enrolled adults with an emergency department encounter for opioid use disorder, the buprenorphine treatment Opioid Hospital Quality Improvement Program (O-HQIP) pathway was associated with significantly increased prescription fills for buprenorphine within 30 days of discharge.
Posted 3/21/2023 (updated 3/27/2024)
Researchers at Indiana University conducted one-on-one interviews with clinical providers and other stakeholders in the recovery arena to better understand the slow uptake of the drug most used to treat opioid use disorder. Biases against buprenorphine was the most consistent theme, though the reason for bias differed amongst stakeholders. Clinical providers and behavioral health care providers preferred the abstinence approach rather than use of medications.
Posted 10/3/2022 (updated 3/27/2024)
The United States overdose crisis continues unabated. Despite efforts to increase capacity for treating opioid use disorder (OUD) in the U.S., how actual treatment receipt compares to need remains unclear. In this cross-sectional study, progress is estimated in addressing the gap between OUD prevalence and OUD treatment receipt at the national and state levels from 2010 to 2019.
Posted 9/7/2022 (updated 3/27/2024)
Buprenorphine (Suboxone) is an effective treatment for opioid use disorder (OUD). However, there have been widespread reports of diversion and misuse. This study examined motivations for nonprescribed buprenorphine use among rural residents.